NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
Clinical Trials
89 trialsNCT04762602 2026-03-27
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Hutchmed
Phase 1 Terminated
NCT05355701 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05538130 2026-03-27
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT06482905 2026-03-24
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech Inc.
Phase 1 Recruiting
NCT07464925 2026-03-20
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT05610891 2026-03-18
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT05916313 2026-03-17
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT07472790 2026-03-16
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Not yet recruiting
NCT07455045 2026-03-06
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT02073994 2026-02-17
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
Phase 1 Completed
NCT02481154 2026-02-17
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Completed
NCT03343197 2026-02-17
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Servier
Phase 1 Completed
NCT03030066 2026-02-04
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Daiichi Sankyo
Phase 1 Active not recruiting
NCT06357377 2026-01-14
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
Phase 1 Not yet recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT06326411 2025-11-10
NST-628
Nested Therapeutics, Inc
Phase 1 Recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04794972 2025-09-29
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06270082 2025-09-19
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
Phase 1 Terminated
NCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT07025018 2025-08-01
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Hutchmed
Phase 1 Recruiting
NCT06773481 2025-07-09
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05362409 2025-06-19
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Alpheus Medical, Inc.
Phase 1 Completed
NCT05226494 2025-06-04
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
NanoPharmaceuticals LLC
Phase 1 Recruiting
NCT00526812 2025-05-28
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
Biogen
Phase 1 Completed
NCT05460507 2025-03-30
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Plus Therapeutics
Phase 1 Recruiting
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT04404569 2024-12-20
ETERNITI
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04771897 2024-12-20
KONQUER
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT06737146 2024-12-17
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Not yet recruiting
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting
NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
NCT03296696 2024-10-29
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Amgen
Phase 1 Terminated
NCT05082493 2024-06-06
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
WPD Pharmaceuticals Sp. z o.o.
Phase 1 Withdrawn
NCT03043391 2024-04-08
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Phase 1 Completed
NCT06305910 2024-03-12
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
OX2 Therapeutics
Phase 1 Recruiting
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT01491893 2023-09-28
PVSRIPO
Istari Oncology, Inc.
Phase 1 Completed
NCT00634231 2023-08-25
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Candel Therapeutics, Inc.
Phase 1 Completed
NCT00751270 2023-08-25
BrTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT04608812 2023-08-18
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OncoSynergy, Inc.
Phase 1 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03332355 2023-05-24
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Vanquish Oncology, Inc.
Phase 1 Terminated
NCT04089449 2023-04-05
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
Phase 1 Completed
NCT01672463 2023-03-29
OKN-007
Oblato, Inc.
Phase 1 Unknown